

## 財務ハイライト // Financial Summary

日本基準 (J-GAAP)

	'07/3	'08/3	'09/3	'10/3	'11/3	'12/3	'13/3
売上高	¥1,790,026	¥1,896,539	¥1,788,223	¥1,620,915	¥1,982,435	¥1,947,884	¥1,952,492
営業利益	139,623	102,397	2,114	51,455	87,957	60,688	45,016
経常利益 (損失)	157,981	92,790	(32,624)	34,957	84,091	50,714	50,252
親会社株主に帰属する当期純利益 (損失)	93,860	63,083	(59,164)	14,723	24,434	5,587	(51,076)
総資産	2,324,906	2,358,929	2,022,553	2,383,906	2,367,314	2,336,953	2,472,091
自己資本	792,538	768,110	544,366	575,368	522,473	486,235	496,500
純資産	1,030,521	1,006,046	775,628	821,436	758,886	720,901	747,482
営業活動によるキャッシュ・フロー	142,917	156,578	78,428	132,872	176,228	124,491	171,595
投資活動によるキャッシュ・フロー	(164,239)	(182,679)	(206,237)	(269,402)	(155,987)	(123,975)	(165,772)
フリー・キャッシュ・フロー	(21,322)	(26,101)	(127,809)	(136,530)	20,241	516	5,823
財務活動によるキャッシュ・フロー	35,558	7,090	112,539	168,709	17,985	2,054	(36,009)
設備投資額 (十億円)	159.8	142.5	134.1	103.2	98.7	155.1	116.1
減価償却費 (十億円)	113.9	125.0	140.7	116.1	147.0	114.9	115.5
研究開発費 (十億円)	97.7	105.4	131.1	117.3	138.1	122.3	125.0
売上高営業利益率 (%)	7.8	5.4	0.1	3.2	4.4	3.1	2.3
売上高当期純利益率 (%)	5.2	3.3	(3.3)	0.9	1.2	0.3	(2.6)
売上高研究開発費比率 (%)	5.5	5.6	7.3	7.2	7.0	6.3	6.4
有利子負債 (十億円)	641.0	673.9	795.4	997.9	1,040.3	1,053.0	1,060.6
D/Eレシオ (倍)	0.6	0.7	1.0	1.2	1.4	1.5	1.4
自己資本比率 (%)	34.1	32.6	26.9	24.1	22.1	20.8	20.1
キャッシュ・フロー対有利子負債比率	4.5	4.3	10.1	7.5	5.9	8.5	6.2
インタレスト・カバレッジ・レシオ (倍)	13.3	13.2	6.5	11.0	13.7	10.2	13.2
金融収支 (十億円)	(3.9)	(2.8)	(2.7)	(5.0)	(6.3)	(4.7)	(5.4)
ROE (%)	12.4	8.1	(9.0)	2.6	4.5	1.1	(10.4)
ROA (%)	4.2	2.7	(2.7)	0.7	1.0	0.2	(2.1)
1株当たり当期純利益 (損失) (円)	56.82	38.20	(35.84)	8.92	14.86	3.42	(31.25)
1株当たり純資産 (円)	479.87	465.21	329.74	348.52	319.61	297.45	303.74
1株当たり配当金 (円)	12.00	12.00	9.00	6.00	9.00	9.00	6.00
配当性向 (%)	21.1	31.4	—	67.3	60.6	263.3	—
PER (倍)	15.7	16.7	(9.3)	51.2	27.9	102.9	(9.4)
PBR (倍)	1.9	1.4	1.0	1.3	1.3	1.2	1.0
従業員数 (人)	24,691	25,588	26,902	27,828	29,382	29,839	30,396
研究開発人員 (人)	3,148	3,392	3,511	3,764	3,933	3,989	3,951
連結子会社数 (社)	105	116	126	143	146	145	162
為替 (円/\$)	116.97	114.44	100.71	92.89	85.74	79.08	82.91
ナフサ価格 (円/KL)	50,000	61,500	58,900	41,200	47,500	54,900	57,500
海外売上高の地域別内訳 (十億円)							
アジア	543.3	591.7	550.5	539.5	744.3	716.3	736.4
北米	46.1	46.1	46.1	75.0	165.4	159.9	176.3
欧州	72.0	67.6	80.4	71.8	90.5	82.9	78.8
中東・アフリカ	43.0	44.1	37.3	21.8	33.2	25.7	24.2
中南米	14.9	17.1	18.2	12.3	13.6	14.4	18.8
オセアニア他	28.5	22.2	17.3	8.5	9.7	9.7	9.4
合計	747.8	788.8	749.8	728.9	1,056.7	1,009.0	1,043.8
海外売上高比率 (%)	41.8	41.6	41.9	45.0	53.3	51.8	53.5

(百万円)

	'14/3	'15/3	'16/3
¥2,243,794	¥2,376,697	¥2,101,764	
100,842	127,346	164,446	
111,109	157,414	171,217	
36,977	52,192	81,451	
2,788,507	2,880,396	2,662,150	
643,297	791,319	766,874	
934,506	1,118,216	1,090,776	
194,362	260,854	261,172	
(135,177)	(56,628)	(53,678)	
59,185	204,226	207,494	
(59,084)	(151,465)	(177,956)	
143.4	84.2	103.8	
115.7	119.2	116.6	
141.3	147.9	155.8	
4.5	5.4	7.8	
1.6	2.2	3.9	
6.3	6.2	7.4	
1,074.6	980.2	831.5	
1.1	0.9	0.8	
23.1	27.5	28.8	
5.5	3.8	3.2	
15.0	19.0	22.6	
(4.9)	0.7	(2.7)	
6.5	7.3	10.5	
1.4	1.8	2.9	
22.62	31.93	49.84	
393.58	484.17	469.25	
9.00	9.00	14.00	
39.8	28.2	28.1	
16.8	19.4	10.2	
1.0	1.3	1.1	
30,745	31,039	31,094	
3,952	3,913	3,831	
164	167	160	
100.17	109.76	120.15	
67,300	63,500	42,800	
883.0	964.0	819.8	
233.0	257.3	306.2	
106.7	96.6	82.3	
29.7	61.9	30.3	
29.3	36.3	37.9	
11.2	12.2	12.7	
1,292.9	1,428.4	1,289.2	
57.6	60.1	61.3	

## 国際会計基準 (IFRS)

(百万円)

	'17/3	'18/3	(監査中) '19/3
売上収益	¥1,939,069	¥2,190,509	¥2,318,572
コア営業利益	184,547	262,694	204,252
営業利益	126,467	250,923	182,972
親会社の所有者に帰属する当期利益	76,540	133,768	117,992
資産合計	2,878,193	3,068,685	3,171,618
親会社の所有者に帰属する持分合計	812,612	927,141	998,702
資本合計	1,115,903	1,252,214	1,351,886
営業活動によるキャッシュ・フロー	185,776	293,250	208,143
投資活動によるキャッシュ・フロー	(205,697)	(154,520)	(180,837)
フリー・キャッシュ・フロー	(19,921)	138,730	27,306
財務活動によるキャッシュ・フロー	(523)	(94,264)	(60,866)
設備投資額 (十億円)	136.3	158.8	163.7
減価償却費 (十億円)	110.3	107.1	112.5
研究開発費 (十億円)	158.0	165.3	163.5
売上収益コア営業利益率 (%)	9.5	12.0	8.8
売上収益当期利益率 (%)	3.9	6.1	5.1
売上収益研究開発費比率 (%)	8.1	7.5	7.1
有利子負債 (十億円)	884.1	842.2	839.5
D/Eレシオ (倍)	0.8	0.7	0.6
親会社所有者帰属持分比率 (%)	28.2	30.2	31.5
キャッシュ・フロー対有利子負債比率	4.8	2.9	4.0
インタレスト・カバレッジ・レシオ (倍)	16.4	27.8	19.0
金融収支 (十億円)	(2.2)	(0.5)	0.2
ROE (%)	9.8	15.4	12.3
ROA (%)	2.8	4.5	3.8
基本的1株当たり当期利益 (円)	46.81	81.81	72.17
1株当たり親会社所有者帰属持分 (円)	496.96	567.04	610.82
1株当たり配当金 (円)	14.00	22.00	22.00
配当性向 (%)	29.9	26.9	30.5
PER (倍)	13.3	7.6	7.1
PBR (倍)	1.3	1.1	0.8
従業員数 (人)	32,536	31,837	32,542
研究開発人員 (人)	4,010	4,034	3,937
連結子会社数 (社)	170	178	184
為替 (円/\$)	108.34	110.85	110.92
ナフサ価格 (円/KL)	34,700	41,900	49,500
海外売上収益の地域別内訳 (十億円)			
アジア	741.1	842.6	936.4
北米	305.8	366.9	380.4
欧州	69.1	85.9	95.1
中東・アフリカ	22.4	37.4	42.3
中南米	34.4	39.5	43.1
オセアニア他	10.7	12.4	8.5
合計	1,183.4	1,384.7	1,505.7
海外売上収益比率 (%)	61.0	63.2	64.9

## 財務ハイライト // Financial Summary

### J-GAAP

	'07/3	'08/3	'09/3	'10/3	'11/3	'12/3	'13/3
Net sales	¥1,790,026	¥1,896,539	¥1,788,223	¥1,620,915	¥1,982,435	¥1,947,884	¥1,952,492
Operating income	139,623	102,397	2,114	51,455	87,957	60,688	45,016
Ordinary income (loss)	157,981	92,790	(32,624)	34,957	84,091	50,714	50,252
Net income (loss) attributable to owners of the parent	93,860	63,083	(59,164)	14,723	24,434	5,587	(51,076)
Total assets	2,324,906	2,358,929	2,022,553	2,383,906	2,367,314	2,336,953	2,472,091
Shareholders' equity	792,538	768,110	544,366	575,368	522,473	486,235	496,500
Net assets	1,030,521	1,006,046	775,628	821,436	758,886	720,901	747,482
Cash flows from operating activities	142,917	156,578	78,428	132,872	176,228	124,491	171,595
Cash flows from investing activities	(164,239)	(182,679)	(206,237)	(269,402)	(155,987)	(123,975)	(165,772)
Free cash flow	(21,322)	(26,101)	(127,809)	(136,530)	20,241	516	5,823
Cash flows from financing activities	35,558	7,090	112,539	168,709	17,985	2,054	(36,009)
Capital expenditure (billions of yen)	159.8	142.5	134.1	103.2	98.7	155.1	116.1
Depreciation and amortization expenses (billions of yen)	113.9	125.0	140.7	116.1	147.0	114.9	115.5
Research and development expenses (billions of yen)	97.7	105.4	131.1	117.3	138.1	122.3	125.0
Operating margin (%)	7.8	5.4	0.1	3.2	4.4	3.1	2.3
Net income ratio to net sales (%)	5.2	3.3	(3.3)	0.9	1.2	0.3	(2.6)
Research and development expenses ratio to net sales (%)	5.5	5.6	7.3	7.2	7.0	6.3	6.4
Interest-bearing liabilities (billions of yen)	641.0	673.9	795.4	997.9	1,040.3	1,053.0	1,060.6
D/E ratio (times)	0.6	0.7	1.0	1.2	1.4	1.5	1.4
Shareholders' equity ratio (%)	34.1	32.6	26.9	24.1	22.1	20.8	20.1
Ratio of interest-bearing debt to cash flow	4.5	4.3	10.1	7.5	5.9	8.5	6.2
Interest coverage ratio (times)	13.3	13.2	6.5	11.0	13.7	10.2	13.2
Net interest expenses (billions of yen)	(3.9)	(2.8)	(2.7)	(5.0)	(6.3)	(4.7)	(5.4)
Return on equity (%)	12.4	8.1	(9.0)	2.6	4.5	1.1	(10.4)
Return on assets (%)	4.2	2.7	(2.7)	0.7	1.0	0.2	(2.1)
Net income (loss) per share (yen)	56.82	38.20	(35.84)	8.92	14.86	3.42	(31.25)
Net assets per share (yen)	479.87	465.21	329.74	348.52	319.61	297.45	303.74
Cash dividends per share (yen)	12.00	12.00	9.00	6.00	9.00	9.00	6.00
Dividend payout ratio (%)	21.1	31.4	—	67.3	60.6	263.3	—
Price earnings ratio (times)	15.7	16.7	(9.3)	51.2	27.9	102.9	(9.4)
Price book-value ratio (times)	1.9	1.4	1.0	1.3	1.3	1.2	1.0
Number of employees	24,691	25,588	26,902	27,828	29,382	29,839	30,396
Number of research and development employees	3,148	3,392	3,511	3,764	3,933	3,989	3,951
Number of consolidated subsidiaries	105	116	126	143	146	145	162
Exchange rate (yen/\$)	116.97	114.44	100.71	92.89	85.74	79.08	82.91
Naphtha price (yen/KL)	50,000	61,500	58,900	41,200	47,500	54,900	57,500
Overseas sales by region (billions of yen)							
Asia	543.3	591.7	550.5	539.5	744.3	716.3	736.4
North America	46.1	46.1	46.1	75.0	165.4	159.9	176.3
Europe	72.0	67.6	80.4	71.8	90.5	82.9	78.8
Middle East and Africa	43.0	44.1	37.3	21.8	33.2	25.7	24.2
Central and South America	14.9	17.1	18.2	12.3	13.6	14.4	18.8
Oceania and others	28.5	22.2	17.3	8.5	9.7	9.7	9.4
Total	747.8	788.8	749.8	728.9	1,056.7	1,009.0	1,043.8
Overseas sales ratio (%)	41.8	41.6	41.9	45.0	53.3	51.8	53.5

(Millions of yen)

	'14/3	'15/3	'16/3
¥2,243,794	¥2,376,697	¥2,101,764	
100,842	127,346	164,446	
111,109	157,414	171,217	
36,977	52,192	81,451	
2,788,507	2,880,396	2,662,150	
643,297	791,319	766,874	
934,506	1,118,216	1,090,776	
194,362	260,854	261,172	
(135,177)	(56,628)	(53,678)	
59,185	204,226	207,494	
(59,084)	(151,465)	(177,956)	
143.4	84.2	103.8	
115.7	119.2	116.6	
141.3	147.9	155.8	
4.5	5.4	7.8	
1.6	2.2	3.9	
6.3	6.2	7.4	
1,074.6	980.2	831.5	
1.1	0.9	0.8	
23.1	27.5	28.8	
5.5	3.8	3.2	
15.0	19.0	22.6	
(4.9)	0.7	(2.7)	
6.5	7.3	10.5	
1.4	1.8	2.9	
22.62	31.93	49.84	
393.58	484.17	469.25	
9.00	9.00	14.00	
39.8	28.2	28.1	
16.8	19.4	10.2	
1.0	1.3	1.1	
30,745	31,039	31,094	
3,952	3,913	3,831	
164	167	160	
100.17	109.76	120.15	
67,300	63,500	42,800	
883.0	964.0	819.8	
233.0	257.3	306.2	
106.7	96.6	82.3	
29.7	61.9	30.3	
29.3	36.3	37.9	
11.2	12.2	12.7	
1,292.9	1,428.4	1,289.2	
57.6	60.1	61.3	

## IFRS

(Millions of yen)

	'17/3	'18/3	(Unaudited) '19/3
Sales revenue	¥1,939,069	¥2,190,509	¥2,318,572
Core operating income	184,547	262,694	204,252
Operating income	126,467	250,923	182,972
Net income attributable to owners of the parent	76,540	133,768	117,992
Total assets	2,878,193	3,068,685	3,171,618
Equity attributable to owners of the parent	812,612	927,141	998,702
Total equity	1,115,903	1,252,214	1,351,886
Cash flows from operating activities	185,776	293,250	208,143
Cash flows from investing activities	(205,697)	(154,520)	(180,837)
Free cash flow	(19,921)	138,730	27,306
Cash flows from financing activities	(523)	(94,264)	(60,866)
Capital expenditure (billions of yen)	136.3	158.8	163.7
Depreciation and amortization expenses (billions of yen)	110.3	107.1	112.5
Research and development expenses (billions of yen)	158.0	165.3	163.5
Core operating income to sales revenue (%)	9.5	12.0	8.8
Net income to sales revenue (%)	3.9	6.1	5.1
Research and development expenses to sales revenue (%)	8.1	7.5	7.1
Interest-bearing liabilities (billions of yen)	884.1	842.2	839.5
D/E ratio (times)	0.8	0.7	0.6
Equity attributable to owners of the parent to total assets (%)	28.2	30.2	31.5
Ratio of interest-bearing debt to cash flow	4.8	2.9	4.0
Interest coverage ratio (times)	16.4	27.8	19.0
Net interest expenses (billions of yen)	(2.2)	(0.5)	0.2
Return on equity (%)	9.8	15.4	12.3
Return on assets (%)	2.8	4.5	3.8
Basic earnings per share (yen)	46.81	81.81	72.17
Equity attributable to owners of the parent per share (yen)	496.96	567.04	610.82
Cash dividends per share (yen)	14.00	22.00	22.00
Dividend payout ratio (%)	29.9	26.9	30.5
Price earnings ratio (times)	13.3	7.6	7.1
Price book-value ratio (times)	1.3	1.1	0.8
Number of employees	32,536	31,837	32,542
Number of research and development employees	4,010	4,034	3,937
Number of consolidated subsidiaries	170	178	184
Exchange rate (yen/\$)	108.34	110.85	110.92
Naphtha price (yen/KL)	34,700	41,900	49,500
Overseas sales revenue by region (billions of yen)			
Asia	741.1	842.6	936.4
North America	305.8	366.9	380.4
Europe	69.1	85.9	95.1
Middle East and Africa	22.4	37.4	42.3
Central and South America	34.4	39.5	43.1
Oceania and others	10.7	12.4	8.5
Total	1,183.4	1,384.7	1,505.7
Overseas sales revenue ratio (%)	61.0	63.2	64.9

## セグメント情報 // Sector Information

			'07/3	'08/3	'09/3
売上高	基礎化学	Basic Chemicals	¥ 314,004	¥ 314,718	¥ 240,030
Net sales	石油化学	Petrochemicals & Plastics	539,065	603,326	552,974
	エネルギー・機能材料	Energy & Functional Materials	—	—	—
	精密化学	Fine Chemicals	90,882	92,937	80,763
IFRS 売上収益	情報電子化学	IT-related Chemicals	266,436	297,515	307,121
IFRS Sales revenue	健康・農業関連事業	Health & Crop Sciences	198,310	200,378	222,202
	医薬品	Pharmaceuticals	234,546	237,592	235,590
	その他	Others	146,783	150,073	149,543
	合計	Total	1,790,026	1,896,539	1,788,223
営業利益 (損失)	基礎化学	Basic Chemicals	13,483	10,559	(15,334)
Operating income (loss)	石油化学	Petrochemicals & Plastics	23,596	4,518	(30,337)
	エネルギー・機能材料	Energy & Functional Materials	—	—	—
	精密化学	Fine Chemicals	13,085	11,430	1,629
IFRS コア営業利益	情報電子化学	IT-related Chemicals	3,457	6,290	(996)
IFRS Core operating income	健康・農業関連事業	Health & Crop Sciences	23,251	20,914	24,429
	医薬品	Pharmaceuticals	56,231	46,464	32,350
	その他	Others	8,012	3,688	(7,891)
	消去	Elimination	(1,492)	(1,466)	(1,736)
	合計	Total	139,623	102,397	2,114
売上高営業利益率 (%)	基礎化学	Basic Chemicals	4.29	3.36	(6.39)
Operating margin (%)	石油化学	Petrochemicals & Plastics	4.38	0.75	(5.49)
	エネルギー・機能材料	Energy & Functional Materials	—	—	—
	精密化学	Fine Chemicals	14.40	12.30	2.02
IFRS 売上収益コア営業利益率 (%)	情報電子化学	IT-related Chemicals	1.30	2.11	(0.32)
IFRS Core operating income to sales revenue (%)	健康・農業関連事業	Health & Crop Sciences	11.72	10.44	10.99
	医薬品	Pharmaceuticals	23.97	19.56	13.73
	その他	Others	5.46	2.46	(5.28)
	合計	Total	7.80	5.40	0.12
設備投資額 (十億円)	基礎化学	Basic Chemicals	24.6	27.6	14.7
Capital expenditure (billions of yen)	石油化学	Petrochemicals & Plastics	16.9	21.2	17.6
	エネルギー・機能材料	Energy & Functional Materials	—	—	—
	精密化学	Fine Chemicals	4.6	6.9	7.7
	情報電子化学	IT-related Chemicals	72.0	33.4	50.6
	健康・農業関連事業	Health & Crop Sciences	10.1	8.5	11.3
	医薬品	Pharmaceuticals	12.5	18.3	12.7
	その他	Others	19.1	26.7	19.6
	合計	Total	159.8	142.5	134.1
設備投資額の内訳 (十億円)	新設・増強	New plants and expansions			
Breakdown of capital expenditure (billions of yen)	基礎化学	Basic Chemicals	18.7	13.1	3.8
	石油化学	Petrochemicals & Plastics	4.3	1.3	2.9
	エネルギー・機能材料	Energy & Functional Materials	—	—	—
	精密化学	Fine Chemicals	1.9	3.1	3.3
	情報電子化学	IT-related Chemicals	66.6	27.6	47.9
	健康・農業関連事業	Health & Crop Sciences	4.7	2.1	2.0
	医薬品	Pharmaceuticals	1.9	11.2	2.9
	その他	Others	5.5	3.2	5.6
	小計	Sub-total	103.6	61.6	68.4
	合理化	Rationalization of production processes	6.8	5.1	6.0
	研究開発	R&D	7.1	6.5	9.6
	更新・補修	Maintenance and renewal	22.6	37.8	23.0
	その他	Others	19.8	31.4	27.2
	合計	Total	159.8	142.5	134.1
減価償却費 (十億円)	基礎化学	Basic Chemicals	13.5	13.2	17.2
Depreciation and amortization expenses (billions of yen)	石油化学	Petrochemicals & Plastics	19.2	18.4	20.9
	エネルギー・機能材料	Energy & Functional Materials	—	—	—
	精密化学	Fine Chemicals	6.5	6.1	6.3
	情報電子化学	IT-related Chemicals	31.5	42.2	39.8
	健康・農業関連事業	Health & Crop Sciences	14.2	12.8	13.1
	医薬品	Pharmaceuticals	16.2	15.4	14.5
	その他	Others	12.8	16.9	29.0
	合計	Total	113.9	125.0	140.7
研究開発費 (十億円)	基礎化学	Basic Chemicals	5.7	6.1	6.4
Research and development expenses (billions of yen)	石油化学	Petrochemicals & Plastics	11.3	11.1	12.0
	エネルギー・機能材料	Energy & Functional Materials	—	—	—
	精密化学	Fine Chemicals	4.2	4.1	4.2
	情報電子化学	IT-related Chemicals	12.6	13.7	21.2
	健康・農業関連事業	Health & Crop Sciences	18.7	19.4	20.7
	医薬品	Pharmaceuticals	42.5	47.8	55.0
	その他	Others	2.6	3.2	11.6
	合計	Total	97.7	105.4	131.1

\*1 2011年3月期から全社共通研究費の配賦方法等を見直している。また一部の連結子会社を「その他部門」からセグメントを変更している(2010年3月期は組替後を掲載)。

\*2 2012年3月期から「精密化学部門」を廃止・再編し、同セグメントの事業を「基礎化学部門」と「農業化学部門」に移管、また「農業化学部門」を「健康・農業関連事業部門」に改称(2011年3月期は組替後を掲載)。

\*3 2016年3月期から、従来の基礎化学部門および石油化学部門の事業を「石油化学事業」と「エネルギー・機能材料事業」に再編し、両事業部門を「石油化学部門」と「エネルギー・機能材料部門」に改組(2015年3月期は組替後を掲載)。

\*4 2017年3月期から、情報電子化学部門に含まれていた電池部材およびエンジニアリングプラスチックをエネルギー・機能材料部門に移管(2016年3月期は組替後を掲載)。

(百万円 Millions of yen)

(百万円 Millions of yen)

日本基準 (J-GAAP)								国際会計基準 (IFRS)		
'10/3*	'11/3*1,2	'12/3*2	'13/3	'14/3	'15/3*3	'16/3*3,4	'17/3*4	'18/3*4	(監査中 Unaudited) '19/3	
¥ 203,294	¥ 302,289	¥ 284,348	¥ 263,522	¥ 286,898	¥ —	¥ —	¥ —	¥ —	¥ —	
481,529	649,885	672,428	693,859	792,021	932,294	657,093	557,852	674,116	757,529	
—	—	—	—	—	202,844	209,007	206,414	250,988	282,850	
86,713	—	—	—	—	—	—	—	—	—	
265,226	322,287	293,066	299,968	362,255	405,126	384,532	358,473	368,709	396,839	
211,546	250,806	264,134	262,580	326,967	345,383	359,013	320,613	339,698	338,094	
267,464	410,614	380,518	378,595	418,809	403,562	435,478	440,974	500,227	492,130	
105,143	46,554	53,390	53,968	56,844	87,488	56,641	54,743	56,771	51,130	
1,620,915	1,982,435	1,947,884	1,952,492	2,243,794	2,376,697	2,101,764	1,939,069	2,190,509	2,318,572	
1,328	20,627	9,349	(6,391)	(10,867)	—	—	—	—	—	
(247)	11,130	6,155	(3,232)	4,942	20,809	28,767	58,884	94,567	61,610	
—	—	—	—	—	783	2,809	6,030	19,189	22,959	
3,579	—	—	—	—	—	—	—	—	—	
6,304	26,138	10,968	11,703	34,898	32,408	19,874	8,714	12,341	26,227	
29,264	23,302	26,495	26,272	38,184	56,117	77,518	47,440	43,964	19,716	
29,889	28,654	20,918	30,857	47,079	29,024	42,686	69,871	94,786	80,764	
6,714	4,128	7,720	7,963	8,373	15,653	7,830	10,146	11,052	9,422	
(25,376)	(26,022)	(20,917)	(22,156)	(21,767)	(27,448)	(15,038)	(16,538)	(13,205)	(16,446)	
51,455	87,957	60,688	45,016	100,842	127,346	164,446	184,547	262,694	204,252	
0.65	6.82	3.29	(2.43)	(3.79)	—	—	—	—	—	
(0.05)	1.71	0.92	(0.47)	0.62	2.23	4.38	10.56	14.03	8.13	
—	—	—	—	—	0.39	1.34	2.92	7.65	8.12	
4.13	—	—	—	—	—	—	—	—	—	
2.38	8.11	3.74	3.90	9.63	8.00	5.17	2.43	3.35	6.61	
13.83	9.29	10.03	10.01	11.68	16.25	21.59	14.80	12.94	5.83	
11.17	6.98	5.50	8.15	11.24	7.19	9.80	15.84	18.95	16.41	
6.39	8.87	14.46	14.76	14.73	17.89	13.82	18.53	19.47	18.43	
3.17	4.44	3.12	2.31	4.49	5.36	7.82	9.52	11.99	8.81	
12.4	16.6	24.5	33.0	22.7	—	—	—	—	—	
14.4	13.7	19.6	14.1	17.0	19.7	20.7	30.6	17.4	31.5	
—	—	—	—	—	5.8	20.6	21.9	22.5	24.3	
17.8	—	—	—	—	—	—	—	—	—	
11.5	27.7	66.9	18.7	51.5	17.5	26.7	33.5	24.5	33.6	
23.2	15.6	19.3	25.1	17.5	16.3	15.5	24.2	56.3	39.9	
7.8	10.5	11.3	14.6	28.7	16.5	13.9	14.9	21.2	16.9	
16.3	14.6	13.5	10.6	6.1	8.3	6.3	11.1	16.8	17.6	
103.2	98.7	155.1	116.1	143.4	84.2	103.8	136.3	158.8	163.7	
—	—	—	—	—	—	—	—	—	—	
1.2	3.4	6.9	18.1	4.0	—	—	—	—	—	
1.9	2.3	6.1	6.8	10.2	2.5	1.8	—	3.2	6.4	
—	—	—	—	—	1.1	10.0	—	14.3	13.0	
11.0	—	—	—	—	—	—	—	—	—	
8.7	23.9	62.2	15.8	48.1	12.9	22.1	—	21.3	28.3	
17.7	7.8	9.2	15.4	8.6	10.6	6.4	—	38.0	22.9	
2.0	0.7	1.7	1.6	1.9	1.6	1.9	—	3.7	6.1	
7.6	5.7	1.0	2.6	0.6	0.9	0.7	—	6.0	8.6	
50.1	43.8	87.1	60.3	73.4	29.6	43.0	—	86.5	85.4	
5.4	4.6	3.9	3.1	4.8	4.5	8.3	—	2.7	2.8	
7.7	6.7	10.6	12.9	13.0	8.3	7.4	—	12.1	13.6	
18.9	23.7	30.3	22.4	27.2	22.7	21.7	—	31.3	43.9	
21.2	19.9	23.2	17.4	25.0	19.1	23.3	—	26.2	17.9	
103.2	98.7	155.1	116.1	143.4	84.2	103.8	136.3	158.8	163.7	
14.2	21.2	14.2	15.5	18.0	—	—	—	—	—	
19.4	18.4	14.1	13.7	12.8	22.6	22.2	22.8	23.0	22.0	
—	—	—	—	—	12.4	11.8	12.7	13.9	15.4	
7.3	—	—	—	—	—	—	—	—	—	
23.2	20.3	14.5	17.9	25.0	33.2	35.0	31.7	29.6	31.1	
12.6	22.3	14.6	15.3	17.7	15.4	16.3	16.2	16.2	18.7	
21.2	47.2	42.3	37.1	28.1	20.9	22.2	15.5	15.1	16.3	
18.4	17.7	15.1	15.9	14.1	14.7	9.2	11.4	9.4	9.0	
116.1	147.0	114.9	115.5	115.7	119.2	116.6	110.3	107.1	112.5	
3.5	5.1	5.2	5.8	6.4	—	—	—	—	—	
8.3	7.6	7.2	7.1	7.6	6.7	6.2	6.2	6.6	7.1	
—	—	—	—	—	8.2	8.0	9.3	7.5	8.5	
4.2	—	—	—	—	—	—	—	—	—	
11.0	11.6	11.7	12.3	15.0	16.5	16.6	16.1	17.3	17.3	
17.2	21.6	19.7	20.6	22.9	24.9	26.8	28.2	29.3	29.3	
54.9	71.2	59.0	61.1	71.9	72.9	83.7	82.3	89.3	85.1	
18.1	21.1	19.5	18.1	17.6	18.7	14.5	15.8	15.3	16.2	
117.3	138.1	122.3	125.0	141.3	147.9	155.8	158.0	165.3	163.5	

\*1 From FY2010, we have revised our method of allocation of R&D expenses for company-wide projects, etc. Certain consolidated subsidiaries, formerly categorized under the Others sector, have been re-categorized. (FY2009 figures have been recalculated using the revised method for purposes of comparison.)

\*2 As of FY2011, the Fine Chemicals Sector was eliminated and reorganized. The businesses in this sector were transferred to the Basic Chemicals Sector or the Agricultural Chemicals Sector. Following this change the Agricultural Chemicals Sector has changed its name to "Health & Crop Sciences" sector. (The amounts for FY2010 have been reclassified by revised sectors.)

\*3 As of FY2015, the Basic Chemicals Sector was eliminated and businesses in this sector were split and transferred to the Petrochemicals & Plastics Sector and Energy & Functional Materials Sector that was established as a new business sector. In addition, a part of businesses in the Petrochemicals & Plastics Sector was transferred to the Energy & Functional Materials Sector. (The amounts for FY2014 have been reclassified by revised sectors.)

\*4 As of FY2016, battery materials and engineering plastics that had been included in the IT-related Chemicals Sector were transferred to the Energy & Functional Materials Sector. (The amounts for FY2015 have been reclassified by revised sectors.)